Furthermore, the expression of ETV2 is transient during development, understanding how other downstream co-factors (i.e., ELK3, FLI1, SCL/TAL1, etc.)direct the developmental machinery following the downregulation of ETV2 will be important for the development of therapeutic strategies using ETV2 to develop mature vasculature that can be used for ischemic diseases such as the transplantation of human vasculature (71, 114). The gene discussed is TAL1; the disease is ischemic disease.